The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial

被引：6

作者：

Zhang, Lei ^{[1
,2
]}

Coombes, Jeff ^{[3
]}

Pascoe, Elaine M. ^{[1
]}

Badve, Sunil V. ^{[1
,4
]}

Dalziel, Kim ^{[5
]}

Cass, Alan ^{[1
,6
]}

Clarke, Philip ^{[5
]}

Ferrari, Paolo ^{[1
,7
]}

McDonald, Stephen P. ^{[1
,8
]}

Morrish, Alicia T. ^{[1
]}

Pedagogos, Eugenie ^{[1
,9
]}

Perkovic, Vlado ^{[1
,10
]}

Reidlinger, Donna ^{[1
]}

Scaria, Anish ^{[1
]}

Walker, Rowan ^{[1
,11
]}

Vergara, Liza A. ^{[1
]}

Hawley, Carmel M. ^{[1
,4
,12
]}

Johnson, David W. ^{[1
,4
,12
]}

机构：

[1] Univ Queensland, Australasian Kidney Trials Network, Brisbane, Qld, Australia

[2] Guangdong Prov Hosp Chinese Med, Dept Nephrol, Guangzhou, Guangdong, Peoples R China

[3] Univ Queensland, Sch Human Movement Studies, Brisbane, Qld, Australia

[4] Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld 4102, Australia

[5] Univ Melbourne, Ctr Hlth Policy Programs & Econ, Melbourne, Vic 3010, Australia

[6] Menzies Sch Hlth Res, Darwin, NT, Australia

[7] Fremantle Hosp, Dept Renal Med, Melbourne, Vic, Australia

[8] Univ Adelaide, Cent Northern Adelaide Renal & Transplantat Serv, Dept Nephrol & Transplantat Serv, Adelaide, SA 5005, Australia

[9] Royal Melbourne Hosp, Dept Nephrol, Melbourne, Vic, Australia

[10] George Inst, Sydney, NSW, Australia

[11] Alfred Hosp, Dept Renal Med, Melbourne, Vic, Australia

[12] Translat Res Inst, Brisbane, Qld, Australia

来源：

REDOX REPORT | 2016年 / 21卷 / 01期

基金：

英国医学研究理事会;

关键词：

Anaemia; Chronic kidney disease; Erythropoiesis-stimulating agent; Oxidative stress; Pentoxifylline; RED-BLOOD-CELL; HEMODIALYSIS-PATIENTS; RESISTANT ANEMIA; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; INFLAMMATION; F-2-ISOPROSTANES; OXPENTIFYLLINE; MODERATE; THERAPY;

D O I：

10.1179/1351000215Y.0000000022

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients. Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities. Results: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD - 6.06 U/l, P = 0.09), or protein carbonyls (MD - 0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04). Conclusions: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.

引用

页码：14 / 23

页数：10

共 32 条

[1] Association between Biomarkers of Carbonyl Stress with Increased Systemic Inflammatory Response in Different Stages of Chronic Kidney Disease and after Renal Transplantation [J].